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Purpose: Following the introduction of medical therapy for benign prostatic hyper-
plasia (BPH), we determined the effect of the change in trends in medical therapy on 
the indication and outcome of surgical intervention for BPH.
Materials and Methods: We compared the basic characteristics of, weight of resected 
tissue of, transfusions in, and postoperative complications of patients who underwent 
surgery between 1985 and 1989 (before the advent of medical therapy for BPH), between 
1995 and 1999 (when medical therapy was developed and became widely used as alter-
native treatment), and between 2005 and 2009 (when medical therapy superseded sur-
gical intervention to become first-line treatment and when combination therapy be-
came widely adopted). 
Results: At our institution, the mean age and BMI of patients increased over the past 
two decades (p＜0.001). Hypertension, operation history, and other comorbidities also 
increased significantly (p＜0.001, p=0.005, and p＜0.001, respectively). The in-
dications for surgery in 1985 to 1989, 1995 to 1999, and 2005 to 2009 were as follows: 
acute urinary retention in 34.7%, 20.2%, and 15.1% of patients and symptomatic deteri-
oration in 61.1%, 72.3%, and 73.0% of patients, respectively. Prostate volume and the 
weight of resected tissue increased from 34.4±14.5 ml to 61.3±32.4 ml and from 7.2±6.4
g to 10.8±7.6 g, respectively, over two decades. Patients who underwent surgery in 2005 
to 2009 had their catheters removed earlier (p＜0.001). Secondary hemorrhage within 
four postoperative weeks and repeat transurethral resection of the prostate within 1 
year decreased significantly (p=0.03 and p=0.003, respectively). No statistically sig-
nificant change in impaired detrusor contractility was found (p=0.523).
Conclusions: Although patients who underwent surgery were older after widespread 
use of medical therapy for BPH, advancements in surgical techniques have benefitted 
these patients. 
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Several decades ago, treatments for benign prostatic hy-
perplasia (BPH) were almost entirely surgical [1]. During 
the 1990s, various minimally invasive surgical procedures 
(MIS) were developed, including transurethral microwave 
thermotherapy, transurethral needle ablation, and tran-
surethral laser vaporization. Although techniques have 
advanced, transurethral resection of the prostate (TURP) 
remains the gold standard surgical intervention for BPH 
[2]. 
The introduction of α-antagonists in the early 1990s re-
sulted in significant improvements in the medical treat-
ment of BPH [3]. After the early 2000s, combination ther-
apy with α-antagonists and 5-α-reductase inhibitors has 
resulted in significant changes in the management of lower Korean J Urol 2012;53:23-28
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urinary tract symptoms (LUTS) secondary to BPH [4]. In 
the Proscar Long-Term Efficacy and Safety and Medical 
Therapy of Prostate Symptoms (MTOPS) studies, medical 
therapy reduced the incidence of urinary retention and the 
need for invasive surgery [5]. Currently, α-blockers and 
5-α-reductase inhibitors are first-line treatments for BPH. 
Nevertheless, many patients continue to undergo surgical 
intervention for BPH. Some patients cannot or will not tol-
erate medical therapy, whereas others experience sympto-
matic deterioration despite long-term medical therapy. 
Despite the advances in medical and surgical inter-
vention, many men continue to suffer from BPH. This con-
dition is associated with a reduction in quality of life (QoL). 
As the average life expectancy increases, the incidence of 
BPH also increases. The incidence of BPH is 50% in men 
between 51 and 60 years of age and as high as 88% in men 
up to 80 years of age [6]. In an aging population, it would 
be advantageous to determine the roles of medical and sur-
gical intervention for BPH and the effect of changes in med-
ical therapy trends on the indications and outcomes of sur-
gical intervention for BPH. The aim of this study was to 
compare the outcomes in patients who underwent surgery 
in 1985 to 1989 (before the widespread use of medical ther-
apy for BPH), in 1995 to 1999 (when medical therapy was 
developed and began to be prescribed as alternative treat-
ment to surgery), and in 2005 to 2009 (when medical ther-
apy superseded surgical intervention to become first-line 
treatment and when combination therapy became widely 
adopted). 
MATERIALS AND METHODS
Medical records were retrospectively reviewed for all pa-
tients who underwent surgery for BPH from 1 January 
1985 to 31 December 1989 (group 1), from 1 January 1995 
to 31 December 1999 (group 2), and from 1 January 2005 
to 31 December 2009 (group 3). University staff urologists 
.with more than 1 year of surgical experience with BPH per-
formed all the operations. Preoperatively, we evaluated 
age, body mass index (BMI), prostate-specific antigen 
(PSA) level, prostate volume, prostate transitional zone 
volume, maximum urinary flow rate, postvoid residual 
urine volume, International Prostate Symptom Score 
(IPSS), QoL score, BPH medication use, and chief 
complaints. Prostate and transitional zone volume were 
measured by transrectal ultrasonography. Postvoid re-
sidual urine volume was measured by ultrasonography. 
BPH medication history included α-blocker or 5-α-reduc-
tase inhibitor therapy for BPH more than 3 months before 
surgery. Patient comorbidity was evaluated on the basis of 
premedication history. The type of surgery was classified 
as open prostatectomy, TURP, or MIS. MIS included tran-
surethral microwave thermotherapy, transurethral nee-
dle ablation, and transurethral laser vaporization. 
Perioperative and postoperative parameters were inves-
tigated representatively in patients who underwent 
TURP, who were divided into 3 subgroups according to time 
period: 1985 to 1989 (subgroup 1), 1995 to 1999 (subgroup 
2), and 2005 to 2009 (subgroup 3). Transfusion and the 
weight of the resected tissue were evaluated as operative 
parameters. The postoperative course was evaluated on 
the basis of length of hospital stay, the postoperative day 
on which the catheter was removed, and postoperative 
complications. A postoperative complication was defined 
as any event requiring additional treatment within 1 year 
of BPH surgery: secondary hemorrhage that required 
transfusion or hospital admission within 4 weeks post-
operatively, impaired detrusor contractility that required 
suprapubic cystostomy as a result of recurrent acute uri-
nary retention (AUR) or failure to void, repeat surgery for 
BPH, urethral stricture that required surgical inter-
vention, long-term stress incontinence, and irritative 
LUTS that required medication use until 1 year 
postoperatively.
For the statistical analysis, one-way analysis of variance 
was used for continuous variables and a chi-square test was 
used for categorical variables to assess differences between 
means. A p value ＜0.05 was considered to be statistically 
significant. SPSS ver. 18.0 (IBM, New York, NY, USA) was 
used for the statistical analysis.
RESULTS
The medical records of 952 men were reviewed and in-
cluded in this study. The basic characteristics of the men 
are shown in Table 1. A total of 190 men underwent surgery 
for BPH in group 1, 484 in group 2, and 278 in group 3. The 
mean ages of the men were 65.4, 65.9, and 69.3 years in 
group 1, group 2, and group 3, respectively. Over time, the 
mean age increased and was significantly different be-
tween group 2 and group 3 (p＜0.001). The comorbidities 
of patients who underwent surgery for BPH are shown in 
Fig. 1. The prevalences of hypertension, a history of sur-
gery, and “others” (e.g., stroke, cancer, and cardiac con-
ditions) increased significantly over time. BMI increased 
gradually over two decades (Table 1). The mean BMIs were 
21.6, 22.9, and 24.0 in group 1, group 2, and group 3, re-
spectively (p＜0.001). The most common indication for sur-
gery in all groups was worsening symptoms, followed by 
AUR. The incidence of symptomatic deterioration con-
tinued to increase, but the rate of AUR kept decreasing. 
Other indications for surgery included bladder stones and 
incidentally detected hydronephrosis (Fig. 2). 
In group 1, only one PSA level was found in the chart re-
view; therefore, group 1 was excluded from the PSA 
comparison. The mean PSA levels of group 2 and group 3 
were 6.8 and 5.8, respectively; however, they were not sig-
nificantly different. The mean prostate volume showed a 
trend similar to that of mean age. There was a slight in-
creasing trend from 34.4 ml to 38.4 ml between group 1 and 
group 2. However, there was a sharp increase between 
group 2 and group 3 (p＜0.001). We could not elucidate suf-
ficient data to analyze prostate transitional zone volume, 
maximum urinary flow rate, residual urine volume, total Korean J Urol 2012;53:23-28
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TABLE 1. Basic characteristics of men undergoing surgical therapy for benign prostatic hyperplasia 
           Variable Group 1 (1985-1989) Group 2 (1995-1999) Group 3 (2005-2009)
No. of patients      190     484     278
Age (yr) 65.4±7.5 65.9±8.8 69.3±8.0
Comorbidity, n (%)
Hypertension   42 (22.1) 163 (33.7) 121 (43.5)
Diabetes   16 (8.4)   50 (10.3)   37 (13.3)
OP history     8 (4.2)   40 (8.3)   32 (11.5)
Others     2 (1.1)   48 (9)   38 (13.7)
BMI 21.6±3.0 22.9±3.0 24.0±2.8
Indication of surgery, n (%)
AUR   66 (34.7)   98 (20.2)   42 (15.1)
Worsening symptoms 116 (61.1) 350 (72.3) 203 (73.0)
Hematuria     4 (2.1)   23 (4.8)   32 (11.5)
UTI     2 (1.1)     5 (1.0)     3 (1.1)
Others   33 (17.4)   23 (4.8)   26 (9.4)
PSA (ng/ml)   6.8±10.8   5.8±7.5
Prostate volume (ml) 34.4±14.5 38.4±21.9 61.3±32.4
Prostate transitional zone volume (ml) 13.9±7.5 39.4±25.8
Maximum urinary flow rate (ml/sec)   8.5±3.5 16.1±34.5 10.8±6.2
Residual urine volume (ml) 105.5±132.8 83.5±116.5
Total IPSS 23.0±7.4 23.0±7.7
QoL   4.6±1.3   4.6±1.0
OP, operation; BMI, body mass index; AUR, acute urinary retention; UTI, urinary tract infection; PSA, prostate-specific antigen; IPSS,
International Prostate Symptom Score; QoL, quality of life.
FIG. 1. The prevalence of comorbidity in patients who underwent 
surgery for benign prostate hyperplasia over three different 
time periods. Statistically significant increases in hypertension, 
operation (OP) history, and others were observed (p＜0.001, 
p=0.005, and p＜0.001, respectively).
FIG. 2. Indications for surgery for benign prostate hyperplasia 
over three different time periods. Acute urinary retention (AUR) 
decreased significantly (p＜0.001), but worsening symptoms 
increased significantly (p=0.01). UTI, urinary tract infection.
IPSS score, and QoL score in group 1. Therefore, we com-
pared groups 2 and 3, and a significant difference was de-
tected in prostate transitional zone volume (p＜0.001) 
(Table 1). 
Only two patients (1.1%) in group 1 required BPH medi-
cation; the remaining patients in this group did not receive 
medical therapy. However, 33.5% of the patients in group 
2 used α-blockers. A marked improvement was observed 
in group 3. α-Blockers were taken by 47.8% of patients, and 
25.9% of patients required combined therapy with an 
α-blocker and a 5-α-reductase inhibitor (Fig. 3).
TURP was the most commonly performed surgical meth-
od during the two decades studied. There were fewer open 
prostatectomies in groups 2 and 3 than in group 1. On the 
other hand, MIS had only begun to be performed with group 
2 (Fig. 4). Of 952 patients, 664 underwent TURP. The basic 
characteristics of these patients were similar to those of pa-
tients who underwent surgery for BPH (Table 1); however, 
one difference was that the mean prostate volume gradu-
ally and significantly increased over the 20-year study peri-
od (p＜0.001). 
We analyzed perioperative and postoperative parame-Korean J Urol 2012;53:23-28
26 Choi et al
TABLE 2. Incidence of perioperative and postoperative variables in men undergoing TURP for BPH
Subgroup 1  Subgroup 2  Subgroup 3 
               Variable
(1985-1989) (1995-1999) (2005-2009)
Perioperative parameters
    Weight of resected tissue (g) 7.2±6.4 5.8±5.1 10.8±7.6
    Transfusion, n (%)  10 (7.6) 15 (4.4)    7 (3.6)
Postoperative parameters
    Hospital stay (day) 16.5±11.3 11.6±5.4   9.5±5.0
    Catheter removed (day) 8.2±4.7 6.7±2.8   6.6±2.7
Complication, n (%)
    Secondary hemorrhage within 4 postoperative weeks    7 (5.3) 16 (4.7) 2 (1)
    Impaired detrusor contractility    6 (4.6) 18 (5.3)  12 (6.2)
    Required re-do TURP(1-yr periods)    14 (10.7) 21 (6.2)    5 (2.6)
    Urethral stricture    5 (3.8) 13 (3.8)    6 (3.1)
    Long-term stress incontinence 0 (0)   2 (0.6) 0 (0)
    Irritative LUTS    2 (1.5)   3 (0.9)    4 (2.1)
    Others    3 (2.3)   4 (1.2) 0 (0)
TURP, transurethral resection of the prostate; BPH, benign prostatic hyperplasia; LUTS, lower urinary tract symptom.
FIG. 3. The prevalence of medical therapy before surgery for 
benign prostatic hyperplasia over three different time periods. 
The prevalence of α-blockers and combination therapy increa-
sed significantly (p＜0.001).
FIG. 4. The types of surgery performed for benign prostatic 
hyperplasia over three different time periods. Transurethral 
resection of the prostate (TURP) was used most frequently over 
all three time periods. MIS, minimally invasive surgery.
ters in subgroups who underwent TURP for direct compar-
ison in one type of surgery: 131 patients in subgroup 1,339 
patients in subgroup 2, and 194 patients in subgroup 3 un-
derwent TURP for BPH. Perioperative parameters and 
postoperative variables for the three patient subgroups are 
illustrated in Table 2. The mean weight of resected tissue 
was significantly greater in subgroup 3 than in subgroup 
1 and subgroup 2. The number of patients who required 
transfusion because of perioperative hemorrhage con-
tinuously deceased over time. Over time, catheters were re-
moved earlier and patients were discharged earlier after 
their operations. Secondary hemorrhage within four post-
operative weeks and the need for repeat TURP within 1 
year after surgery decreased significantly (p=0.03 and 
p=0.003, respectively). The number of patients who re-
quired suprapubic cystostomy gradually increased over 
time, albeit not significantly so (p=0.523). No significant 
changes in any of the other complications were found in the 
three studied periods.
DISCUSSION
Over the past two decades, medical therapy has been the 
standard first-line therapy for BPH [5,7]. The conclusion 
of the Korean study was similar to that of the MTOPS study 
[8]. Long-term combination therapy reduced the incidence 
of AUR and BPH surgery. In our study, AUR decreased sig-
nificantly, but worsening symptoms increased signifi-
cantly. Our results confirmed an increasing trend in 
α-blocker monotherapy and combination therapy with 
5-α-reductase inhibitors after the 1990s, when medical 
therapy became widespread. This finding was in line with Korean J Urol 2012;53:23-28
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global trends. However, surgery for BPH is still required 
and TURP became the mainstay of surgical intervention 
for BPH. Although medical therapy is appropriate for pa-
tients with symptomatic BPH, it has obvious limitations. 
Failure of medical therapy results in worsening LUTS and 
recurrent AUR. In this study, the most common chief com-
plaint was worsening symptoms followed by AUR. In a 
study by Izard and Nickel [9], chronic urinary retention in-
creased substantially, from 14.6 to 39.3 between 1988 and 
2008. 
Our hypothesis was that medical therapy for BPH would 
delay surgical intervention. Patients who finally required 
surgery were inevitably older, had worse health con-
ditions, and had more advanced disease. Therefore, late 
surgical intervention could result in poorer outcomes asso-
ciated with worse postoperative complications. In this 
study, the mean age of patients who underwent surgery 
was greater in the 1990s than in the 1980s, and the increase 
was larger after 10 years. As medical therapy became more 
common, the mean age increased. This trend was also 
shown in another study. According to Vela-Navarrete et al. 
[10], patients who underwent surgery for BPH in 2002 were 
significantly older than those who underwent surgery in 
1992, by a mean of 3.1 years. Anamnesis also increased 
with mean age. A considerable number of patients had hy-
pertension and previous surgical and other medical histor-
ies in the 2000s. We concluded that the increasing co-
morbidity was due to aging, advancement in diagnostic 
techniques, and increasing health concerns. A higher BMI 
is associated with a higher risk of comorbidity [11,12]. The 
decreased AUR and the increased frequency of sympto-
matic deterioration were due to combination therapy that 
reduced AUR [8]. 
According to our results, the mean prostate volume in-
creased during the 20 year period in patients who under-
went surgical intervention for BPH. A review by Han et al. 
[13] showed that the mean prostate volume in surgically 
managed patients over 5 successive years increased sig-
nificantly, from 37.1 ml to 53.6 ml, between 1998 and 2002. 
They attributed these findings to the priority given to medi-
cal therapy by patients who required surgery in the past 
and to development of the endoscopic technique, which ex-
tended the indication of TURP. Because of larger prostate 
volumes, it is natural that the weight of the resected tissue 
increased correspondingly. This study showed that the 
mean prostate volume was significantly greater in group 
3 than in group 1; simultaneously, the weight of the re-
sected tissue was also significantly greater in subgroup 3 
than in subgroup 1. Shin and Park [14] reported that the 
mean resection volume increased with both TURP and 
open prostatectomy between 1999 and 2010. Reich et al. 
[15] evaluated 10,654 patients who underwent TURP and 
showed that mortality and morbidity were closely asso-
ciated with the weight of tissue resected. According to 
Mebust et al. [16], increased morbidity was seen in patients 
with a gland size greater than 45 g and an age greater than 
80 years. According to our survey of perioperative and post-
operative variables, the length of hospital stay, the number 
of days to catheter removal, and the number of trans-
fusions, secondary hemorrhages, and repeat TURPs de-
ceased with time. These findings were due to advance-
ments in surgical techniques, experience, and improved in-
struments [17]. We believed that critical outcomes such as 
impaired detrusor contractility would be poor and hypothe-
sized that long-term bladder outlet obstruction would im-
pair bladder detrusor contractility. Saito et al. [18] experi-
mented with rat bladders and found that whole-bladder 
pressure was significantly lower in rats subjected to 
long-term outflow obstruction than in controls. However, 
the number of suprapubic cystostomies required after 
TURP did not increase significantly, because new techni-
ques and equipment reduced the number of complications 
and overcame the risks associated with aging [14,17]. In 
addition, combination therapy resolved bladder outlet ob-
struction and protected progress to impaired detrusor con-
tractility [8,19]. The results showed that surgical inter-
vention conferred benefits to patients, despite their older 
ages and larger prostate volumes at the time of surgery.
Our analysis of data spanning two decades was limited 
by selection bias. We surveyed all patients who had under-
gone surgery for BPH. Following the widespread adoption 
of medical therapy for the treatment of BPH, the rate of 
medical therapy increased and the number of surgeries de-
creased [13,20]. Although this study did not represent all 
BPH patients, it analyzed data spanning two decades to de-
termine the changing trends in surgery for BPH. However, 
because of its retrospective nature, IPSS and transitional 
zone volume data were not available in the 1980s. An addi-
tional limitation was the lack of pre- and postoperative da-
ta, such as IPSS data and maximum urinary flow rates, 
with which to compare the direct results of surgery. 
Furthermore, we were unable to determine the length of 
time required to complete the surgeries-a variable that is 
useful in determining the skill level of surgeons when re-
section weights are identical. Instead, we used transfusion 
history in the perioperative period to indirectly determine 
the level of surgical skill and care. The length of hospital 
stay appeared to be longer in the current study than in other 
studies [9,10,21], which was due to Korean health in-
surance policies and patient tendencies. The mean number 
of hospitalizations in subgroup 3 in the current study was 
similar to that in other Korean publications [22,23]. 
Recently, surgical intervention began evolving as medi-
cal treatment. New technologies such as laser and bipolar 
electrodes have been widely used. Several studies reported 
that these technologies have led to shorter hospital stays, 
shorter catheterization periods, and fewer complications 
[17,24]. Even in patients with large prostate volumes, in 
whom TURP was inappropriate in the past, these proce-
dures have shown excellent results, especially concerning 
perioperative blood loss [25]. Continued advancement in 
surgical intervention is expected to overcome challenges 
due to aging and large prostate volume. Korean J Urol 2012;53:23-28
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CONCLUSIONS
The ages and comorbidities of patients who underwent sur-
gery for BPH increased over the two decades studied. Our 
study showed that the mean prostate volume at the time 
of surgery was significantly greater than it was 20 years 
ago, as was the weight of the resected tissue. Although 
these conditions can increase the risk of complications, the 
prevalence of secondary hemorrhage within four post-
operative weeks and the need for repeat TURP within 1 
year after surgery decreased significantly. Furthermore, 
no significant differences in the prevalence of other compli-
cations were observed. Although patients who underwent 
surgery were older after widespread use of medical therapy 
for BPH, advancements in surgical techniques have bene-
fitted these patients.
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